Efficacy of rituximab in refractory neuromyelitis optica

Conclusions:
RTX is an effective and well-tolerated treatment in RNMO. BMI could be a predictive factor for efficacy.

Source: Multiple Sclerosis - June 1, 2016 Category: Neurology Authors: Collongues, N., Brassat, D., Maillart, E., Labauge, P., Ouallet, J., Carra-Dalliere, C., Moreau, T., Bourre, B., Papeix, C., Brochet, B., Audoin, B., Vukusic, S., de Seze, J., Marignier, R., on behalf of the OFSEP and CFSEP Tags: Short Reports Source Type: research